Enzo Biochem (ENZ) Stock Price, News & Analysis

Company Overview

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Key Stats

• Today's Range: $0.31 to $0.36
• 50-Day Range: $0.33 to $0.66
• 52-Week Range: $0.31 to $1.30
• Volume: 704,380 shs
• Average Volume: 125,477 shs
• Market Capitalization: $17.03 million
• P/E Ratio: N/A
• Dividend Yield: 123.08%
• Price Target: N/A
• Consensus Rating: N/A

Enzo Biochem Stock Analysis - MarketRank™

Enzo Biochem scored higher than 10% of companies evaluated by MarketBeat, and ranked 906th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Enzo Biochem.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Enzo Biochem has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.83% of the float of Enzo Biochem has been sold short.

Short Interest Ratio / Days to Cover

Enzo Biochem has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enzo Biochem has recently increased by 14.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Enzo Biochem is a leading dividend payer. It pays a dividend yield of 93.79%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Enzo Biochem does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.83% of the float of Enzo Biochem has been sold short.

Short Interest Ratio / Days to Cover

Enzo Biochem has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enzo Biochem has recently increased by 14.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Enzo Biochem this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enzo Biochem insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.40% of the stock of Enzo Biochem is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 36.90% of the stock of Enzo Biochem is held by institutions.

ENZ Stock Analysis - Frequently Asked Questions

How have ENZ shares performed this year?

Enzo Biochem's stock was trading at $0.7143 at the beginning of 2025. Since then, ENZ stock has decreased by 54.5% and is now trading at $0.3250.
View the best growth stocks for 2025 here.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its earnings results on Monday, March, 17th. The medical research company reported ($0.02) earnings per share for the quarter. The medical research company earned $7.33 million during the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative trailing twelve-month return on equity of 7.96%.

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzo Biochem investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and OneLife Technologies (OLMM).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 4/01/2025
• Next Earnings (Estimated): 6/11/2025
• Fiscal Year End: 7/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NYSE:ENZ
• CIK: 316253
• Web: www.enzo.com
• Phone: (212) 583-0100
• Fax: 212-679-7999
• Employees: 520
• Year Founded: 1976

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-26,080,000.00
• Net Margins: -75.34%
• Pretax Margin: -23.79%
• Return on Equity: -7.96%
• Return on Assets: -5.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.55
• Quick Ratio: 2.28

Sales & Book Value

• Annual Sales: $29.09 million
• Price / Sales: 0.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 52,403,000
• Free Float: 46,288,000
• Market Cap: $17.03 million
• Optionable: Optionable
• Beta: 0.80